Daxor Corp (DXR)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$8.63-3.14%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · DXR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -2.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 11 industry peers · Company calendar date is not available
Why it matters: A big change in value can show how investors feel. This helps us understand the market.
Watch forValuation improves by more than 10 points after the next earnings report.
Also watch forValuation declines further by more than 5 points after the next earnings report.
Why it matters: If peers like Lilly or AbbVie show strong valuation, it may reflect positively on Daxor. It could also highlight competitive pressures.
Watch forPeer valuation scores are getting better. This shows a good market environment.
Also watch forPeer valuation scores are going down. This shows a tough market for everyone.
Why it matters: If revenue growth drops, it may indicate a slowdown in Daxor's business. This could impact future earnings.
Worry ifDaxor's revenue growth falls below the sector median, confirming a slowdown.
Less concerning ifRevenue growth is higher than the sector average. This shows ongoing strength.
Why it matters: A drop in sector revenue growth could signal a slowdown affecting Daxor Corp's performance.
Worry ifSector revenue growth falls below its historical median of 24%.
Less concerning ifSector revenue growth is still higher than its usual level.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$183 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $431 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,102 loss on $10,000 · 41.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If peers like Lilly or AbbVie shift to 'neutral' or 'full', it could affect Daxor's market position.
Watch forA peer like Lilly or AbbVie changes from 'expensive' to 'neutral'.
Also watch forPeers maintain or worsen their 'expensive' status.
Why it matters: If revenue growth picks up, it could signal a stronger market position for Daxor.
Supportive ifRevenue growth speeds up to over 12% each year.
Worry ifRevenue growth remains below 9% year over year.
Why it matters: If health care revenue growth speeds up, it could benefit Daxor's market position.
Supportive ifHealth care revenue growth accelerates back toward 12% or higher.
Worry ifRevenue growth is below 9%. This shows the sector is still slowing down.